This inventor holds 2 USPTO granted patents. Top assignee: Kohjin Co., Ltd.. Active years: 1976.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1976
Title: Hideo Suehiro: Innovator in Pharmaceutical Chemistry
Introduction
Hideo Suehiro is a notable inventor based in Kokubunji, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that have therapeutic applications. With a total of 2 patents, his work focuses on innovative processes that enhance the efficacy of medicinal compounds.
Latest Patents
Suehiro's latest patents include a process for preparing 2-thioadenosine. This process is crucial as it serves as an intermediate for the preparation of S-substituted-2-thioadenosines, which possess platelet aggregation inhibitory activity and coronary vasodilating activity. The method involves reacting 5-amino-1-.beta.-D-ribofuranosylimidazole-4-carboxamide oxime or an O-substituted oxime with carbon disulfide in a closed reaction zone at temperatures ranging from about 50°C to about 200°C in a solvent. Additionally, he has developed S-substituted-2-thioadenosines represented by a specific formula, which are useful as platelet aggregation inhibitors and coronary vasodilators.
Career Highlights
Hideo Suehiro is associated with Kohjin Co., Ltd., where he applies his expertise in pharmaceutical innovation. His work has been instrumental in advancing the understanding and application of thioadenosine derivatives in medical treatments.
Collaborations
Suehiro has collaborated with notable colleagues such as Kiyomi Kikugawa and Motonobu Ichino. Their combined efforts have contributed to the successful development of innovative pharmaceutical solutions.
Conclusion
Hideo Suehiro's contributions to pharmaceutical chemistry through his patents and collaborative efforts highlight his role as an influential inventor in the field. His work continues to pave the way for advancements in therapeutic applications.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile